Phase 2 study for nonmetastatic extremity high‐grade osteosarcoma in pediatric and adolescent and young adult patients with a risk‐adapted strategy based on ABCB1/P‐glycoprotein expression: An…

Overview of attention for article published in Cancer (0008543X), February 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 74,277 followers.

Survival for patients with non-metastatic, extremity, P-glycoprotein+, high-grade osteosarcoma improved with a risk-adapted strategy based on P-glycoprotein: 5-year EFS 69.8%, 5-year OS 81.2% https://t.co/o7OxKIowE4 #osteosarcoma #AYA #Pediatrics #sarc…

@VivekSubbiah @JournalCancer @IRCCS_Rizzoli @IstTumori @unito Given link shows error, here's the alternative link; https://t.co/Ptl7RKVwj3 https://t.co/ibbDBCG7Pd

⭐️Phase 2 study for nonmetastatic extremity high‐grade osteosarcoma in pediatric and adolescent and young adult patients with a risk‐adapted strategy based on ABCB1/P‐glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS‐2) @JournalCancer https…

Mifamurtide added to ifosfamide may be a valid option for high risk osteosarcoma patients. Learn more: https://t.co/zinZ3g00Ob @IRCCS_Rizzoli @IstTumori @unito https://t.co/F4kyUGFcC1

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.